Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Teens Influenced By Movie Characters Who Smoke, Both The Good Guys And The Bad Guys
Dartmouth researchers have determined that movie characters who smoke, regardless of whether they are "good guys" or "bad guys," influence teens to try smoking. The study, published in the July 2009 issue of the journal Pediatrics, is titled "Adolescent Smoking: Who Matters More, Good Guys or Bad Guys?"

Daily Women's Health Policy Report Summarizes Research In Breast, Ovarian Cancer
The following summarizes recent articles on breast and ovarian cancer research.~ Breast cancer: For the first time, a large international breast cancer study to determine the effectiveness of radiation therapy after mastectomy will include 200 Chinese women, the New York Times reports. Asian women traditionally have had relatively low breast cancer rates. However, that trend is reversing in China, where breast cancer is on the rise because of rapid urbanization, pollution and diet changes. In addition, China"s one-child policy could be contributing to the trend, as breast cancer is less common in women with more children. Chief researcher Ian Kunkler, a professor at the Edinburgh Cancer Research Center, said that although pharmaceutical companies have done clinical trials of chemotherapy drugs in China, "no patient in China has ever been recruited into a randomized controlled trial for breast radiotherapy." Kunkler"s trial will include about 3,700 participants overall from Australia, Britain and other parts of Europe, Japan and Singapore (Caryn Rabin, New York Times, 8/3).~ Ovarian cancer: Two recently published studies have provided new insight into the early stages of ovarian cancer, potentially increasing the likelihood of developing better diagnostic tests, the Wall Street Journal reports. A study published in the journal Nature Genetics has identified a common gene variation called BNC2. Scientists predict that when BNC2 is combined with other gene variations, the result dramatically increases the risk of ovarian cancer. Researchers involved in a study published in the online journal PLoS have determined that ovarian tumors of the BRCA1 mutation exist in the body for about four years before metastasizing but remain less than one centimeter in diameter during that time. They also found that only about half of the tumors grow to be three centimeters in diameter when they do spread (Beck, Wall Street Journal, 8/4).
News of the day
Workshop Develops Research Roadmap For Focused Ultrasound Treatment Of Brain Disorders
The primary objective of this workshop was to develop a comprehensive R&D roadmap that would fast-track the use of focused ultrasound technology to treat a variety of brain disorders including benign and malignant tumors, Parkinson"s disease and essential tremor, stroke, and epilepsy.
Mental Health

Turkish Ministry Of Health Purchases Two CyberKnife(R) Systems

Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced that the Turkish Ministry of Health has purchased two CyberKnife(R) Robotic Radiosurgery Systems for installation in Ankara and Istanbul, Turkey. Turkey"s first CyberKnife System was installed at Anadolu Medical Center in January 2005. A second system was installed in Turkey at Hacettepe University Hospital in May 2007. In addition to the two recent purchases by the Ministry of Health, a fifth System for installation within Turkey was recently purchased by Istanbul University, Oncology Institute, a leading academic institution in Capa district, Istanbul. The sales of these Systems were coordinated by local distributor Radontek Ltd. "The Turkish Ministry of Health"s purchase of two CyberKnife Systems is further validation of the System"s worldwide clinical acceptance, particularly amongst government institutions," said Euan S. Thomson, Ph.D., president and CEO of Accuray Incorporated. "Full body radiosurgery with the CyberKnife System has truly established itself as a viable treatment alternative for cancer patients around the world." The CyberKnife Systems for Ankara and Instanbul were purchased by the Turkish Ministry of Health for Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi (Ankara) and Dr. Lutfu Kirdar Kartal Egitim ve Arastirma Hastanesi (Istanbul). About the CyberKnife(R) Robotic Radiosurgery System The CyberKnife Robotic Radiosurgery System is the world"s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames. About Accuray Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 60,000 patients worldwide and currently more than 164 systems have been installed in leading hospitals in the Americas, Europe and Asia. Safe Harbor Statement The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to commercialization of products, clinical studies, and regulatory review and approval are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management"s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q filed on May 6, 2009 and our other filings with the Securities and Exchange Commission. The Company"s actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accuray Incorporated


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009